STAT+: Vertex kidney disease drug scrutinized for infection risk

Vertex’s drug is widely expected to secure FDA approval, but a previously undisclosed pause rule has raised questions about the drug’s label Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54. This is the online version of Adam’s Biotech Scorecard, a weekly newsletter featuring exclusive, spicy analysis on the biotech industry. Sign up here to get it delivered to your inbox. Spain is amazing. I was in Madrid for five days covering the ESMO conference. Now, I’m delivering this newsletter to you from a balcony overlooking the Mediterranean. Vertex kidney disease drug scrutinized for infection risk ahead of FDA approval decision Adam Feuerstein/STAT So many medical meetings, so little time. While I was in Madrid reporting on cancer drugs, kidney disease specialists and the investors and analysts who tag along were in Denver for the annual meeting of the American Society of Nephrology. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.